Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLGW) Cash from Operations (2016 - 2017)

Bone Biologics (BBLGW) has disclosed Cash from Operations for 2 consecutive years, with 931700.0 as the latest value for Q4 2017.

  • Quarterly Cash from Operations rose 26.51% to 931700.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was 3330096.0 through Dec 2017, up 54.56% year-over-year, with the annual reading at 2700000.0 for FY2025, 34.54% up from the prior year.
  • Cash from Operations for Q4 2017 was 931700.0 at Bone Biologics, down from 561035.0 in the prior quarter.
  • The five-year high for Cash from Operations was 561035.0 in Q3 2017, with the low at 2527032.0 in Q1 2016.